share_log

New Data Published In Journal of the National Cancer Institute Demonstrate Veracyte's Decipher Prostate Genomic Classifier May Improve Identification Of Aggressive Prostate Cancer In African American Men

New Data Published In Journal of the National Cancer Institute Demonstrate Veracyte's Decipher Prostate Genomic Classifier May Improve Identification Of Aggressive Prostate Cancer In African American Men

发表在美国国家癌症研究所杂志上的新数据表明,Veracyte的解密前列腺癌基因组分类器可以提高对非裔美国男性侵袭性前列腺癌的识别
Benzinga Real-time News ·  2022/09/22 08:58
Veracyte, Inc. (NASDAQ:VCYT) announced that data published today in the Journal of the National Cancer Institute demonstrate that the company's Decipher Prostate Genomic Classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease. The data, from the prospective, multi-site VANDAAM Phase 2 clinical study, suggest that the genomic test may offer a robust improvement over clinical factors alone in risk-stratifying prostate cancer among African American men, which may help reduce disparities in prostate cancer outcomes.
Veracyte,Inc.(纳斯达克代码:VCYT)宣布,今天发表在《美国国家癌症研究所杂志》证明该公司的解密前列腺癌基因组分类器可能有助于识别患有早期局部前列腺癌的非裔美国人,他们最有可能患有更具侵袭性的疾病。来自前瞻性、多部位VANDAAM第二阶段临床研究的数据表明,在非洲裔美国男性中前列腺癌的风险分层方面,基因组测试可能会比单独的临床因素提供强有力的改善,这可能有助于减少前列腺癌结果的差异。
"While African American men have both higher incidence and mortality associated...
Moffitt癌症中心...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发